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adverse cardiovascular events at 30 days and 1 year among three
groups. There was signiﬁcant improvement in the change of end-
diastolic volume (LVEDV) in HP-BMC group compared with N-BMC
or control at 12 months (P<0.05). No differences were observed in
the change of left ventricular ejection fraction (LVEF), left ven-
tricular end-systolic volume (LVESV) or wall motion score index
(WMSI) among three groups. Nonetheless LVESV were decreased in
the HP-BMCs group compared with baseline (P<0.05, within
group), but not the N-BMCs or control group. WMSI was improved
in HP-BMCs and N-BMCs group (P<0.05, within group), but not in
control. The ratio of myocardial perfusion defect determined
by SPECT decreased in HP-BMCs and N-BMCs groups (P<0.05,
within group), but no signiﬁcant differences were observed among
three groups.
CONCLUSIONS Our results provide the ﬁrst-in-man evidence that
intracoronary administration of HP-BMCs following acute MI appears
to be safe and feasible. These results provide the basis for future
prospective randomized clinical trials in a larger patient cohort.
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Circulating miR-499 are novel and sensitive biomarker of acute
myocardial infarction
Lizhu Zhang, Xi Chen, Tong Su, Heng Li, Qiang Huang, Dan Wu,
Zhijun Han, Chengjian Yang
Wuxi Second People’s Hospital of Nanjing Medical University
OBJECTIVES The aim of this study was to investigate the value of
plasma microRNA-499 (miR-499) as a novel biomarker for early
diagnosis of acute myocardial infarction (AMI).
METHODS Enrolled in this study were 227 patients with chest pain on
presentation to the departments of emergency and cardiology of Wuxi
Second People’s Hospital between October 2011 and May 2014. Addi-
tional 100 healthy individuals who received physical examination in
the same hospital during the same period were used as control.
Plasma was collected at admission, and the abundance of miR-499
was measured using reverse transcriptase-polymerase chain reaction
(RT-PCR).
RESULTS MiR-499 was signiﬁcantly elevated in 142 patients diag-
nosed with AMI as compared with 85 patients in non-AMI group and
100 subjects in healthy control group. Plasma miR-499 were already
detectable in the plasma as early as 1 h after onset of chest pain in AMI
patients, and continued to increase gradually without any sign of
decreasing tendency within 9 h in AMI patients. miR-499 was highly
positively correlated with the serum creatine kinase-MB (CK-MB) and
cTnI. The area under the curve (AUC) of miR-499 for the diagnosis
of AMI was 0.86, with an optimal cut-off value of 4.79, sensitivity of
80%, and speciﬁcity of 80.28%.
CONCLUSIONS miR-499 was shown to substantially increase the
diagnostic accuracy of CK-MB and cTnI in the diagnosis of AMI, and
therefore it may prove to be a useful marker for early diagnosis
of AMI.
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Xanthine oxidase inhibition prevents atrial remodeling and atrial
ﬁbrillation in alloxan-induced diabetic rabbits
Jianping Zhao, Jiuchun Qiu, Jian Li, Xue Liang, Yajuan Yang,
Zhiwei Zhang, Guangping Li, Tong Liu
Department of Cardiology, Second Hospital of Tianjin Medical
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OBJECTIVES Accumulating evidence suggests that xanthine oxidase
(XO) activation is one of the major sources of reactive oxygen species
(ROS) and may play an important role in the initiation and perpetu-
ation of atrial ﬁbrillation (AF). XO inhibitor allopurinol may exert
beneﬁcial effects on diabetes-related atrial remodeling. We aimed to
investigate the potential beneﬁts of allopurinol on atrial remodeling
and atrial ﬁbrillation (AF) promotion in alloxan-induced diabetic
rabbits.
METHODS 48 alloxan-induced diabetic rabbits were randomly
divided into three groups (16 for each): diabetic group (DM group),
diabetic allopurinol treatment group (DA group, 25mg/day/kg) and
control group (C group). Eight rabbits in each group were respec-
tively used to electrophysiological study, and another eight rabbits
from each group were monitored hemodynamics and recorded SBP,
DBP and LVEDP and then sacriﬁced to histological study and western
blotting analysis. After 8-week treatment, isolated Langendorffperfused rabbit hearts were used to evaluate atrial electrophysio-
logical parameters and vulnerability to AF which examined by burst
and S1S2 pacing. Collagen volume fraction (CVF) was calculated by
Masson staining. Western-blot analysis was applied to assess atrial
protein expression of ERK, P38, p-P38, JNK, TGF-band NF-kB p50 in
left atrial tissue.
RESULTS There were no signiﬁcant difference regarding SBP, DBP,
LVEDP and AERP in the three groups. Intra-atrial conduction time
(IACT) was prolonged and AF inducibility was increased in DM group
(41/240 vs. 3/240, P<0.05) compared with controls, which were
markedly reduced by allopurinol (41/240 vs. 4/240, P <0.05). Allo-
purinol also attenuated atrial structural remodeling, with signiﬁcant
reduction in CVF. Western-blot analysis revealed DM increased pro-
tein expression of ERK, P38, p-P38, JNK, TGF-band NF-kB p50, which
were reduced by allopurinol.
CONCLUSIONS Allopurinol suppresses AF promotion by preventing
atrial electrical and structural remodeling, which may be due to its
anti-inﬂammatory and anti-oxidative characteristics. These results
suggest that XO activation may play an important role in the diabetes-
related atrial remodeling.
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OBJECTIVES The study aims to explore whether the FKBP12.6 is the
causative gene of HCM, further more to provide new sight for HCM in
molecular genetics research, clinical diagnosis and treatment.
METHODS In reference to Chinese experts consensus in 2007, Amer-
ican Cardiology Foundation / America Heart Association (ACCF/AHA)
in 2011 and European Society of Cardiology (ESC) issued guidelines for
the diagnosis and management of hypertrophic cardiomyopathy. The
study was approved by hospital ethics committee and all subjects
were gave a written informed consent, we enrolled in Thirty seven
HCM patients and collected the clinical data and peripheral venous
blood (2-5 mL). Genome DNA was extracted from peripheral venous
blood. All exons and exon- intron junctions of the FKBP12.6 gene were
screened to determine whether there are gene variances via direct
sequencing. Control group: two hundred healthy individuals with
same ethnic background.
RESULTS
1. Thirty seven patients with HCM were enrolled in the study. There are
twenty three men and fourteen women, the mean age of these pa-
tients was 54.2415.84 years. Two patients with deﬁnite family his-
tory of HCM, besides one patient with family history unexplained
sudden death. The echocardiogram or cardiac magnetic reso-
nance revealed that thickness of interventricular septal was
19.343.903 mm, thickness of left ventricular posterior wall was 11.0
(10.00, 13.00) mm and ten patients with left ventricular outﬂow tract
obstruction. ST-T change was the most common manifestation on
ECG, the incidence was up to 72.97%, atrial arrhythmia up to 32.4%,
ventricular arrhythmia up to 29.73%, block and Wolf-Parkinson-
White syndrome up to 5.41%, pathological Q wave up to 10.81%.
2. One patient with two single nucleotide polymorphisms (SNP) was
identiﬁed by gene sequencing, including FKBP12.6- c.4161T >
C(NM_004116.3:c.38-36T >C), T-to-C substitution at nucleotide site
4161, c.11278A>T (NM_054033.2:c.198þ 57A >T), A-to-T substitution
at nucleotide site 11278. The above SNP were located at exon- intron
junctions. The patient was 35-year-old female was diagnosed as
asymmetric hypertrophic obstructive cardiomyopathy, cardiac ar-
rhythmias: atrial Beckoning tachycardia, atrial premature beat. The
main symptom was recurrent syncope in 13 years, without previous
history of hypertension, diabetes, hyperthyroidism history, The
echocardiogram showed that thickness of intervent - ricular septal
was 20mm, thickness of left ventricular posterior wall was 9mm and
SAM sign was positive.
CONCLUSIONS This study is the ﬁrst to explore the molecular
genetic relationship between FKBP12.6 gene and HCM. We ﬁnd that
two SNP located at the intron of FKBP12.6 gene, which is lower
than the frequency of healthy people reported by 1000 Genomes
Project Database. In our conclusion, FKBP12.6 gene may not be the
causative gene of HCM, but it still needs to increase the sample size
to further conﬁrm.
